ID26330A - Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi - Google Patents

Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi

Info

Publication number
ID26330A
ID26330A IDW20000983A ID20000983A ID26330A ID 26330 A ID26330 A ID 26330A ID W20000983 A IDW20000983 A ID W20000983A ID 20000983 A ID20000983 A ID 20000983A ID 26330 A ID26330 A ID 26330A
Authority
ID
Indonesia
Prior art keywords
polipeptides
modificated
vitamin
modificated polipeptides
Prior art date
Application number
IDW20000983A
Other languages
English (en)
Indonesian (id)
Inventor
Gary L Nelsestuen
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of ID26330A publication Critical patent/ID26330A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IDW20000983A 1997-10-23 1998-10-20 Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi ID26330A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides

Publications (1)

Publication Number Publication Date
ID26330A true ID26330A (id) 2000-12-14

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000983A ID26330A (id) 1997-10-23 1998-10-20 Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi

Country Status (30)

Country Link
US (1) US6017882A (fr)
EP (2) EP1090128B1 (fr)
JP (1) JP4276379B2 (fr)
KR (1) KR20010031370A (fr)
CN (1) CN1246462C (fr)
AP (1) AP2000001811A0 (fr)
AR (2) AR020048A1 (fr)
AT (1) ATE390486T1 (fr)
AU (1) AU749279C (fr)
BR (1) BR9814611A (fr)
CA (1) CA2307175C (fr)
DE (1) DE69839313T2 (fr)
DK (1) DK1090128T3 (fr)
EA (1) EA200000449A1 (fr)
ES (2) ES2303362T3 (fr)
HR (1) HRP20000234A2 (fr)
HU (1) HU225993B1 (fr)
ID (1) ID26330A (fr)
IL (1) IL135603A0 (fr)
IS (1) IS5449A (fr)
MY (1) MY136336A (fr)
NO (1) NO20002025L (fr)
NZ (1) NZ504114A (fr)
PL (1) PL194194B1 (fr)
PT (1) PT1090128E (fr)
SG (1) SG105547A1 (fr)
TR (1) TR200001105T2 (fr)
TW (1) TW587081B (fr)
WO (1) WO1999020767A1 (fr)
ZA (1) ZA989597B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1237917A2 (fr) * 1999-11-19 2002-09-11 Eli Lilly And Company Derives de proteine c
AU2001232736A1 (en) 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
WO2001059084A1 (fr) 2000-02-11 2001-08-16 Eli Lilly And Company Derives de la proteine c
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6828306B2 (en) * 2000-07-31 2004-12-07 Ottawa Heart Institute Research Corporation Charged lipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1370649A1 (fr) * 2001-03-02 2003-12-17 T.A.C. Thrombosis and Coagulation AB Variantes de prot ine c
WO2003073980A2 (fr) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Variants de proteine c recombines
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
BR0309576A (pt) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CA2490342C (fr) 2002-06-21 2015-06-16 Novo Nordisk A/S Compositions solides stabilisees de polypeptides de facteur vii
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
JP4885707B2 (ja) 2003-03-18 2012-02-29 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト セリンプロテアーゼを含むｇｌａ−残基の生産方法
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
DE602004025576D1 (de) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
EP1711513B1 (fr) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration de compositions liquides contenant le facteur vii pour eliminer des virus
ES2676644T3 (es) 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
EP2368579A1 (fr) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Conjugaison au moyen de transglutaminase de peptides
CN101098883B (zh) 2004-12-23 2013-01-23 诺和诺德医疗保健公司 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
EP1924689B1 (fr) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Purification de polypeptides du facteur vii par chromatographie d'interaction hydrophobe
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2059527B1 (fr) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Glycoprotéines modifiées
WO2008078189A2 (fr) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Compositions de facteur vii et viia
WO2008127702A2 (fr) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Polypeptides du facteur vii modifiés et leurs utilisations
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
AU2008345231B2 (en) 2007-12-27 2014-09-11 Takeda Pharmaceutical Company Limited Cell culture processes
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
WO2011074578A1 (fr) * 2009-12-14 2011-06-23 国立大学法人北海道大学 Peptides conférant une perméabilité cellulaire à une structure de membrane lipidique et/ou améliorant la perméabilité cellulaire de ladite structure, et structure de membrane lipidique contenant un lipide lié à ce peptide, en tant que lipide constitutif, et présentant une perméabilité cellulaire ou une perméabilité cellulaire améliorée
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87688B (pt) * 1987-06-12 1992-09-30 Hoechst Japan Processo para a preparacao de proteina hibrida c
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
CA2074839C (fr) * 1990-01-29 2000-11-14 Kathleen L. Berkner Proteines anticoagulantes modifiees de facteur vii
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
HUP0102257A2 (hu) 2001-09-28
JP4276379B2 (ja) 2009-06-10
JP2001520042A (ja) 2001-10-30
ZA989597B (en) 1999-04-23
TW587081B (en) 2004-05-11
AU2702499A (en) 1999-05-10
PL340284A1 (en) 2001-01-29
DE69839313D1 (de) 2008-05-08
EA200000449A1 (ru) 2000-12-25
NO20002025L (no) 2000-06-19
ATE390486T1 (de) 2008-04-15
AU749279B2 (en) 2002-06-20
PL194194B1 (pl) 2007-05-31
EP1676919A1 (fr) 2006-07-05
CN1246462C (zh) 2006-03-22
PT1090128E (pt) 2008-04-17
AU749279C (en) 2004-09-16
IS5449A (is) 2000-04-14
CN1283231A (zh) 2001-02-07
CA2307175A1 (fr) 1999-04-29
HUP0102257A3 (en) 2003-09-29
AR020048A1 (es) 2002-04-10
AP2000001811A0 (en) 2000-06-30
WO1999020767A1 (fr) 1999-04-29
EP1676919B1 (fr) 2014-07-23
ES2303362T3 (es) 2008-08-01
KR20010031370A (ko) 2001-04-16
DE69839313T2 (de) 2009-04-16
NO20002025D0 (no) 2000-04-18
EP1090128B1 (fr) 2008-03-26
AR035786A2 (es) 2004-07-14
HRP20000234A2 (en) 2001-08-31
EP1090128A1 (fr) 2001-04-11
HU225993B1 (en) 2008-02-28
US6017882A (en) 2000-01-25
IL135603A0 (en) 2001-05-20
MY136336A (en) 2008-09-30
NZ504114A (en) 2002-10-25
SG105547A1 (en) 2004-08-27
CA2307175C (fr) 2009-04-14
DK1090128T3 (da) 2008-06-23
TR200001105T2 (tr) 2000-09-21
ES2496104T3 (es) 2014-09-18
BR9814611A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
ID26334A (id) Morfolinol yang aktif secara farmasi
ID26509A (id) Komponen-komponen yang mengandung tetrahidrolipstatin
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
DE69834353D1 (de) Leistungsteilungs-/-addierschaltung
ID24118A (id) Terapi gabungan
DK1124779T3 (da) D-vitaminanaloge forbindelser
DE69814349D1 (de) Befeuchtendes mittel
DK0808833T3 (da) D3-vitamin-analoger
FI973847A0 (fi) Anordning vid en skyddsanordning
ID26317A (id) Formulasi pelepasan yang diperpanjang
ID21770A (id) Plester yang mengandung felbinak
FI971898A0 (fi) Anordning vid en anestesievaporator
FI970925A0 (fi) Anordning vid anestesianlaeggningar
ID24431A (id) Lateks-lateks yang tahan gosokan
FI971744A0 (fi) Anordning vid cirkulationssmoerjningssystem
FI973293A0 (fi) Arrangemang vid verktyg
FI974129L (fi) Apuväline
ATA132398A (de) Verschleissteil
FI972138A0 (fi) Returtraog i bestrykningsanordning
SE9704790D0 (sv) Vitaminkomposition
FI970507A0 (fi) Anordning vid utformningsanordning foer vindrutemellanfolie
ID18330A (id) Suatu produk adisi yang mengandung uretan
FR2765481B1 (fr) Complexe amino-lipidique vitamine